NeoVax

BIOLOGICAL5 trials

Sponsors

Patrick Ott, MD, PhD, Dana-Farber Cancer Institute, Washington University School of Medicine

Conditions

GlioblastomaKidney CancerLymphocytic LeukemiaMelanomaMetastatic MelanomaOvarian Cancer

Phase 1

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

Active, not recruitingNCT02950766

Patrick Ott, MD, PhDKidney Cancer

Start: 2019-03-03End: 2030-05-30Target: 19Updated: 2026-02-03

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

RecruitingNCT03219450

Dana-Farber Cancer InstituteLymphocytic Leukemia

Start: 2021-08-18End: 2028-03-31Target: 15Updated: 2025-05-22

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

TerminatedNCT03422094

Washington University School of MedicineGlioblastoma

Start: 2018-10-31End: 2020-12-31Updated: 2021-10-27

NeoVax With Nivolumab in Patients With Ovarian Cancer

Active, not recruitingNCT04024878

Dana-Farber Cancer InstituteOvarian Cancer

Start: 2020-11-20End: 2029-04-30Updated: 2025-06-18

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Active, not recruitingNCT04930783

Dana-Farber Cancer InstituteMelanoma, Metastatic Melanoma

Start: 2022-01-03End: 2030-09-30Updated: 2026-03-25

Related Papers

Selection of targeted neoantigens for ongoing personalized cancer vaccine trials at Dana Farber Cancer Institute 2189

The Journal of Immunology2025-11-01

A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.

2025-02-0569 citations

Abstract 1174: Incorporation of multisector analysis into the design of personalized DNA vaccines for patients with newly diagnosed glioblastoma

Cancer Research2024-03-221 citations

Abstract A083: Personalized targeted circulating tumor DNA (ctDNA) and T-cell responses after combined neoantigen vaccine and immune checkpoint blockade in ovarian cancer

Cancer Research2024-03-041 citations

Abstract PR015: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma

Cancer Research2023-08-152 citations

Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy

Frontiers in Immunology2022-09-2926 citations